TY - JOUR
T1 - Antigen folding improves loading efficiency and antitumor efficacy of PC7A nanoparticle vaccine
AU - Wilhelm, Jonathan
AU - Quiñones-Pérez, Manuel
AU - Wang, Jian
AU - Wang, Xu
AU - Basava, Vijay S.
AU - Gao, Jinming
N1 - Funding Information:
This work was supported by the National Institutes of Health (R01CA216839 and U01CA218422) and Mendelson-Young Endowment in Cancer Therapeutics. We thank Dr. Chad Brautigam and Dr. Shih-Chia Tso of the UT Southwestern Macromolecular Biophysics Resource for assistance with circular dichroism experiments.
Funding Information:
This work was supported by the National Institutes of Health ( R01CA216839 and U01CA218422 ) and Mendelson-Young Endowment in Cancer Therapeutics . We thank Dr. Chad Brautigam and Dr. Shih-Chia Tso of the UT Southwestern Macromolecular Biophysics Resource for assistance with circular dichroism experiments.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/1/10
Y1 - 2021/1/10
N2 - Cancer vaccines hold great promise to produce antigen-specific T cell immunity for personalized therapy of cancer. Previously, we reported an ultra-pH-sensitive nanoparticle, PC7A, capable of priming an efficacious immune response without significant systemic toxicity. Despite the early success, the relationship between antigen properties and encapsulation efficiency for downstream immune activation remains poorly understood. In this study, we investigated a small library of melanoma antigens and the effects of several formulation methods on the efficiency of peptide loading inside PC7A nanoparticles. Results show loading efficiency is not highly dependent on the formulation methods, but instead mainly driven by the peptide antigen properties. In particular, we identified a phase transition event, namely the folding of antigenic peptides from random coils to α-helical structure, is important for antigen loading inside PC7A nanoparticles. Mutation of a peptide that abrogates the formation of helical structure resulted in poor loading efficiency. Antitumor efficacy studies in melanoma-bearing mice demonstrate the importance of peptide loading in vaccine-induced antitumor immunity. This study highlights the contribution of phase transition of peptide antigens on vaccine formulation in order to make widespread use of personalized nanoparticle vaccines feasible.
AB - Cancer vaccines hold great promise to produce antigen-specific T cell immunity for personalized therapy of cancer. Previously, we reported an ultra-pH-sensitive nanoparticle, PC7A, capable of priming an efficacious immune response without significant systemic toxicity. Despite the early success, the relationship between antigen properties and encapsulation efficiency for downstream immune activation remains poorly understood. In this study, we investigated a small library of melanoma antigens and the effects of several formulation methods on the efficiency of peptide loading inside PC7A nanoparticles. Results show loading efficiency is not highly dependent on the formulation methods, but instead mainly driven by the peptide antigen properties. In particular, we identified a phase transition event, namely the folding of antigenic peptides from random coils to α-helical structure, is important for antigen loading inside PC7A nanoparticles. Mutation of a peptide that abrogates the formation of helical structure resulted in poor loading efficiency. Antitumor efficacy studies in melanoma-bearing mice demonstrate the importance of peptide loading in vaccine-induced antitumor immunity. This study highlights the contribution of phase transition of peptide antigens on vaccine formulation in order to make widespread use of personalized nanoparticle vaccines feasible.
KW - Antigen delivery
KW - Cancer vaccine
KW - Peptide encapsulation
KW - Secondary structure
KW - Ultra-pH sensitive micelles
UR - http://www.scopus.com/inward/record.url?scp=85097646602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097646602&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2020.11.056
DO - 10.1016/j.jconrel.2020.11.056
M3 - Article
C2 - 33301836
AN - SCOPUS:85097646602
SN - 0168-3659
VL - 329
SP - 353
EP - 360
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -